Figure 1 Current treatments for PNETs

Slides:

Advertisements

Similar presentations

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

Advertisements

Samsung Genome Institute Samsung Medical Center

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Anesthes. 2012;116(4): doi: /ALN.0b013e31824b9512 Figure Legend:

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Childhood craniopharyngioma

Figure 1 Framework for variant interpretation of phaeochromocytomas and/or paragangliomas (PPGLs) susceptibility genes into five classes based on the likelihood.

Figure 2 Coronary vessels in atherosclerosis

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Figure 1 Cellular processes involved in cancer development

Figure 5 Schematic illustration of different clinical trial designs

Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era Joon H. Uhm, MD, Alyx B. Porter,

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Potential pathways directly linking obesity with cancer.

Figure 5 MRI of childhood craniopharyngioma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?

Management of advanced renal cancer

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 3 Defects in the T cell receptor signalling pathway

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

Nat. Rev. Urol. doi: /nrurol

Figure 2 Oestrogen receptor signalling pathways

Figure 2 Intracellular actions of metformin

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Oestrogen biosynthesis and production sites in the body

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Drug cycling with collateral sensitivity

Molecular approaches to HER2 targeted therapy

Figure 3 Physiological regulation of autophagy in the heart

Nat. Rev. Endocrinol. doi: /nrendo

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

Figure 4 Tracheal endoscopy in two patients

to the liver and promote patient-derived xenograft tumour growth

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Neurol. doi: /nrneurol

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Template for standard pelvic lymphadenectomy

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Figure 2 Approaches to improve CAR-T-cell therapy

Nat. Rev. Endocrinol. doi: /nrendo

Inhibition of mammalian target of rapamycin: Two goals with one shot?

Nat. Rev. Urol. doi: /nrurol

Vascular Endothelial Growth Factor (VEGF) Pathway

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 The VEGF family of growth factors

Detection rate for EGFR mutations in cfDNA.

Nat. Rev. Endocrinol. doi: /nrendo

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Nat. Rev. Urol. doi: /nrurol

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Presentation transcript:

Figure 1 Current treatments for PNETs Figure 1 | Current treatments for PNETs. Medical therapy includes drugs and antibodies that target different pathways in cancer cells. Surgery involves the removal or resection of the pancreatic neuroendocrine tumour (PNET). Radiological treatment involves particles or high-frequency waves being delivered externally or internally (for instance, intra-arterially) to the tumour. IFNAR, interferon α/β receptor; mTOR, mechanistic target of rapamycin; RTK, receptor tyrosine kinase; SSA, somatostatin analogue; SSTR, somatostatin receptor; VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor. Frost, M. et al. (2018) Current and emerging therapies for PNETs in patients with or without MEN1 Nat. Rev. Endocrinol. doi:10.1038/nrendo.2018.3